Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
OwnerJin Luinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-target immunoglobulin derived proteins, including isolated nucleic acids that encode at least one anti-target Ig derived protein, target, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
Claims33
At least one isolated target Ig derived protein, comprising at least one target binding sequence and at least one portion of at least heavy chain variable region comprising at least one of 10-125 contiguous amino acids of at least one of SEQ ID NOS:1-9, or at least one FR1, FR2, FR3 or FR4 fragment thereof as described in Table 5, further optionally comprising at least one substitution, insertion or deletion as provided in FIGS. 1-42.
At least one isolated target Ig derived protein, comprising at least one target binding sequence and at least one portion of at least one light chain variable region comprising at least one of 10-75 contiguous amino acids of at least one of SEQ ID NOS:10-31, or at least one FR1, FR2, FR3 or FR4 fragment thereof as described in Table 5, further optionally comprising at least one substitution, insertion or deletion as provided in FIGS. 1-42.
At least one isolated target Ig derived protein, comprising at least one target binding sequence and at least one portion of at least one heavy chain constant region comprising at least one of 10-384 contiguous amino acids of at least one of SEQ ID NOS:3240, or at least one CH1 , hinge1, hinge2, hinge 3, hinge4, CH2, or CH3 fragment thereof as described in Table 5, further optionally comprising at least one substitution, insertion or deletion as provided in FIGS. 1-42.
At least one isolated target Ig derived protein, comprising at least one target binding sequence and at least one portion of at least one light chain constant region, comprising at least one of 10-107 contiguous amino acids of at least one of SEQ ID NOS:4142.
At least one isolated target Id derived protein, comprising at least one target binding sequence and at least 10-384 contiguous amino acids of at least one of SEQ ID NOS:1-42, or at least one FR1, FR2, FR3, FR4, CH1, hinge1, hinge2, hinge 3, hinge4, CH2, or CH3 fragment thereof as described in Table 5, further optionally comprising at least one substitution, insertion or deletion as provided in FIGS. 1-42.
Any invention described herein.
Dependencies are inferred from the claim text.